Gain Therapeutics (NASDAQ:GANX) Issues Quarterly Earnings Results

Gain Therapeutics (NASDAQ:GANX) posted its quarterly earnings results on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15), Zacks reports.

Gain Therapeutics Stock Down 5.4%

Gain Therapeutics stock traded down $0.16 during trading on Friday, hitting $2.83. 1,184,912 shares of the company were exchanged, compared to its average volume of 441,440. The company has a market capitalization of $102.56 million, a P/E ratio of -4.64 and a beta of 0.13. The business’s 50 day moving average is $1.92 and its 200 day moving average is $1.83. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $3.06. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.09.

Institutional Trading of Gain Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Gain Therapeutics by 2.9% during the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares in the last quarter. Marshall Wace LLP increased its stake in Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after buying an additional 80,407 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Gain Therapeutics during the 3rd quarter worth approximately $68,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Gain Therapeutics in the 3rd quarter worth approximately $47,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, October 13th. BTIG Research reissued a “buy” rating and set a $9.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Maxim Group raised their target price on Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Roth Capital dropped their price target on Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $7.86.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.